언어 선택

PLAU

PLAU 분자 정보

영어 이름	Urokinase plasminogen activator	시판 약물 수	4
임상 약물 수	5	표적 별명	PLAU，uPA，Plasminogen Activator， Urokinase，Urokinase-Type Plasminogen Activator，Plasminogen Activator， Urinary，BDPLT5，U-PA，ATF，QPD，URK，EC 3.4.21，EC:3.4.21.73，U-Plasminogen Activator，EC 3.4.21.73
최고 연구 개발 단계	Approved

영어 이름	Urokinase plasminogen activator
표적 별명	PLAU，uPA，Plasminogen Activator， Urokinase，Urokinase-Type Plasminogen Activator，Plasminogen Activator， Urinary，BDPLT5，U-PA，ATF，QPD，URK，EC 3.4.21，EC:3.4.21.73，U-Plasminogen Activator，EC 3.4.21.73
시판 약물 수	4
임상 약물 수	5
최고 연구 개발 단계	Approved

PLAU 제품 목록

속성
Protein (2)
제품 라이브러리
온라인 (2)
종
Human (2)
태그
His Tag (2)
마커
Unconjugated (2)

제품 번호	종	발현 시스템	제품 설명	단백질 구조	순도	특성
PLU-H5228	Human	HEK293	Human PLAU / uPA Protein, His Tag (activated by trypsin) (active enzyme)
PLU-H5229	Human	HEK293	Human PLAU / uPA Protein, His Tag

총 수량2

PLAU분자 배경

Urokinase - type plasminogen activator is also known as PLAU and UPA, a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys – Pro – Gly - Arg560 - Val561 – Val – Gly – Gly – Cys in plasminogen to form plasmin. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium.uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction).

PLAU분자 별명

Urokinase,PLAU,ATF,UPA,URK,u-PA,BDPLT5,QPD

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
tPA/HisproUK (Thrombolytic Science)	TS-01	Phase 2 Clinical	Thrombolytic Science	Ischemic Stroke	상세
Upamostat Hydrogen Sulphate	WX-671; LH-011; RHB-107	Phase 2 Clinical	Wilex AG	Coronavirus Disease 2019 (COVID-19); Metastatic breast cancer; Pancreatic Neoplasms	상세
Microlyse	TGD-001	Phase 2 Clinical	University Medical Centre Utrecht, Netherlands	Ischemic Stroke; Purpura, Thrombotic Thrombocytopenic; Thrombocytopenia; Thrombotic Microangiopathies	상세
Recombinant annexin A5 (Annexin Pharmaceuticals)	ANXV; ANXV (Annexin A5); ANXV (Human Recombinant Annexin A5)	Phase 2 Clinical	Annexin Pharmaceuticals AB	Anemia, Sickle Cell; Cardiovascular Diseases; Diabetic Retinopathy; Neoplasms; Retinal Vein Occlusion	상세
MSB-03	MSB-03	Phase 1 Clinical	MatriSys Bioscience Inc	Rosacea	상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Urokinase biosimilar (Sedico)		Approved	Sedico	Angikinase	Egypt	Thromboembolism; Myocardial Infarction; Pulmonary Embolism	Sedico	2014-01-01	Myocardial Infarction; Pulmonary Embolism; Thromboembolism	상세
Tisokinase	AK-124	Approved	Asahi Kasei Corp, Kowa Dental Health Co Ltd	Plasvata, Hapase	Japan	Myocardial Infarction; Thrombosis	null	1991-01-01	Myocardial Infarction; Thrombosis	상세
Urokinase biosimilar (Bharat Serums & Vaccines)	U-FRAG	Approved	Bharat Serums And Vaccines Ltd						Pulmonary Embolism	상세
Nasaruplase	GE-0943	Approved	Mitsubishi Pharma Corp	Tomieze, Thrombolyse	Japan	Myocardial Infarction; Venous Thrombosis	Mitsubishi Pharma Corp	1992-01-01	Myocardial Infarction; Venous Thrombosis	상세